Saltar al contenido
Merck

Severe cholestatic jaundice associated with piroxicam.

Gastroenterology (1991-12-01)
K S Hepps, G M Maliha, R Estrada, R W Goodgame
RESUMEN

A 62-year-old man with rheumatoid arthritis developed jaundice while taking piroxicam. A full evaluation including ultrasound, computerized tomography, endoscopic cholangiography, and liver biopsy confirmed the diagnosis of intrahepatic cholestasis. The patient's jaundice and all other liver function abnormalities normalized 4 months after he discontinued taking piroxicam. This is the first case report in the United States of severe liver toxicity associated with piroxicam. The six cases in the English-language literature are reviewed, featuring the presentation, patterns of liver injury, and outcome in each. Piroxicam should be considered as a potential cause of cholestatic jaundice when other more common etiologies have been excluded.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
Piroxicam, ≥98% (TLC)
En este momento no podemos mostrarle ni los precios ni la disponibilidad
USP
Piroxicam, United States Pharmacopeia (USP) Reference Standard
En este momento no podemos mostrarle ni los precios ni la disponibilidad
Piroxicam for system suitability, European Pharmacopoeia (EP) Reference Standard
En este momento no podemos mostrarle ni los precios ni la disponibilidad
Sigma-Aldrich
Piroxicam, meets USP testing specifications
En este momento no podemos mostrarle ni los precios ni la disponibilidad
Piroxicam, European Pharmacopoeia (EP) Reference Standard
En este momento no podemos mostrarle ni los precios ni la disponibilidad